This October
the most-stacked GH secretagogue on the internet had its compounding door sealed in 2024
In October 2026, CJC-1295 is still prominently listed on telehealth platforms marketing growth hormone secretagogue protocols to US patients. Search traffic for the compound runs at roughly 25,000 monthly queries in October 2026 — down six percent from its 2025 peak, but consistent with the sustained interest that keeps a compound in clinical use discussions. Two weeks ago, this site covered ipamorelin — the peptide CJC-1295 is almost always stacked with — and the political loop of RFK Jr. claiming ipamorelin would be brought back to compounding. CJC-1295's regulatory story runs parallel. On December 4, 2024, the FDA's Pharmacy Compounding Advisory Committee evaluated five separate chemical forms of CJC-1295 for inclusion on the 503A Bulks List. The votes: 0 for, 13 against, for the free base. 0-13 for the DAC free base. 0-13 for both DAC salt variants. 1-12 for the acetate. Sixty-four of sixty-five possible committee votes went against compounding authorization. After the July 2026 PCAC session — the one that backed six other peptides including BPC-157, semax, and KPV — [the Project Biohacking newsletter's August 2026 analysis](https://projectbiohacking.beehiiv.com/p/cjc-1295-ipamorelin-pcac-vote-503a-status) of the PCAC schedule confirmed that neither CJC-1295 nor ipamorelin appeared on that agenda, or on the next scheduled docket before February 2027. Regulated compounding access for CJC-1295 is closed and not scheduled to reopen. The telehealth marketing did not slow.
The molecule
CJC-1295 is a 30-amino-acid GHRH analog engineered to stay in circulation for days
Native growth hormone releasing hormone has a plasma half-life measured in minutes — it triggers a pulse of GH secretion, then clears. CJC-1295 is a modified version of the GHRH 1-29 fragment with four amino acid substitutions and a fatty-acid side chain engineered to bind albumin in the bloodstream. That albumin binding dramatically extends active duration: human pharmacokinetic data shows a single injection producing measurable GH and IGF-1 elevations lasting six to eleven days. [The PubMed literature search for CJC-1295](https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295) covers the published biology across both the modified and non-DAC variants. The mechanism targets the GH axis at the pituitary level. CJC-1295 activates GHRH receptors on somatotroph cells, stimulating endogenous GH secretion — it does not directly deliver growth hormone, it instructs the pituitary to release more of its own. The IGF-1 downstream follows from that GH elevation. ConjuChem Biotechnologies, the original developer, designed the albumin-binding modification to make less-frequent dosing pharmacologically feasible. The compound with the Drug Affinity Complex modification is marketed as CJC-1295 with DAC; a version without that modification circulates faster but does not last as long. Both chemical forms received negative PCAC votes in December 2024.
The stack
the marketing pitch is body composition and longevity — the human evidence is one Phase 1 trial
CJC-1295 appears in fitness, recovery, and longevity stacks with consistent framing: it extends GH pulsing without the blunted natural GH secretion that exogenous growth hormone produces, it pairs cleanly with ipamorelin because the two activate separate receptor pathways — GHRH receptor and ghrelin receptor — and the combination is positioned as a lower-risk entry into GH-axis optimization compared to direct GH injection. The longevity clinic pitch is specific: pulse your own pituitary rather than bypass it. What drives that framing is not a completed body composition trial. [ClinicalTrials.gov tracks the registration history of CJC-1295's clinical program](https://clinicaltrials.gov/search?term=CJC-1295). A Phase 2 was initiated, then discontinued — one of the participating subjects died during the trial; the attending physician concluded the death was most likely unrelated to study drug, but the compound was not advanced. The body-composition, recovery, and longevity narrative in clinical optimization circles is built on endocrine markers from Phase 1 pharmacokinetic work, not on clinical outcomes data. The gap between the endocrine signal and the optimization claim is wide, and the internet routinely treats them as equivalent.
What the data says
the 2006 Phase 1 human study confirmed GH signaling — and the clinical program stopped there
The primary human study for CJC-1295, published in 2006, was a randomized, double-blind, placebo-controlled Phase 1 dose-escalation trial in healthy adults and older adults. [The PubMed record at 17018654](https://pubmed.ncbi.nlm.nih.gov/17018654/) documents the primary findings: a single injection produced GH increases of 2- to 10-fold above baseline lasting six days or more, and IGF-1 elevations persisting nine to eleven days. Multiple-dose data showed further IGF-1 increases with elevation lasting 28 days after the final injection. The published short-term safety profile in that cohort was clean. These are the findings that inform every downstream claim about CJC-1295's mechanism and optimization potential. What that trial established is pharmacokinetics and acute endocrine signal. It did not establish that those endocrine changes translate into the clinical outcomes — body composition, recovery rate, biological age markers — that GH-axis optimization framing describes. The FDA's scientific staff cited this gap explicitly in the December 2024 PCAC session: the stated concern was insufficient data to conclude CJC-1295 would not raise safety concerns similar to those associated with approved growth hormone therapies. [The FDA's bulk drug compounding safety framework](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) documents how GH-axis concerns of that kind are assessed in the compounding authorization context.
Early human — PeptideFactCheck stance
the evidence is real but narrow — and the regulatory record is not ambiguous
CJC-1295 holds PeptideFactCheck's Early human tier. Human evidence exists — the 2006 Phase 1 study is a real trial with real signal, and the GH and IGF-1 pharmacokinetics are established. The evidence is not mature: there is no completed Phase 2 efficacy trial, no Phase 3, and no approved labeling. The Early human tier's definition applies directly: small, preliminary, or narrow human studies exist, but the evidence is not mature. Interesting enough to watch. Too early for broad certainty. The regulatory record adds a layer the evidence tier alone does not capture. Sixty-four of sixty-five December 2024 PCAC votes went against 503A compounding authorization across the five CJC-1295 chemical forms reviewed. The committee's stated concern was insufficient safety data to conclude the compound would not raise GH-axis-related risks similar to those from approved growth hormone therapies. The July 2026 PCAC meeting — which backed KPV, BPC-157, and four other peptides — did not include CJC-1295. The next scheduled docket before February 2027 does not include it. The compounding access is not a pending decision; it is a closed one. The stack that defines CJC-1295's consumer identity — paired with ipamorelin, marketed as a pituitary-level alternative to exogenous GH — operates in a regulatory vacuum that the marketing around it does not explain. Evidence tier: Early human. Votes: in the December 2024 record. Source trail before certainty.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.